Arca
Skip to content

Anovulation

Drug research and approvals for anovulation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 7 studies of anovulation are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 1 approved and 0 open orphan designations naming it, and the EU has 6 authorised medicines for it.

  • Recruiting worldwide: 7
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 1
  • EU medicines: 6

Recruiting Now

Newest start dates first, of 7 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

3 approved, 2 in phase 3, 4 in phase 2, 2 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Choriogonadotropin alfa, Follitropin alfa, Follitropin delta

Follitropin
Phase 3 Follicle stimulating hormone receptor agonist
Urofollitropin
Phase 3 Follicle stimulating hormone receptor agonist
Clomiphene
Phase 2 Estrogen receptor alpha modulator
Gonadotropin, chorionic
Phase 2 Luteinizing hormone/Choriogonadotropin receptor agonist
Anastrozole
Phase 2 Cytochrome P450 19A1 inhibitor
Letrozole
Phase 2 Cytochrome P450 19A1 inhibitor
Paroxetine
Phase 1 Serotonin transporter inhibitor
Clarithromycin
Phase 1 Bacterial 70S ribosome inhibitor

How Its Trials Ended

59 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 8 whose ending is known, 50% met their primary endpoint, 0% missed it and 50% stopped early.

  • Completed, result not reported3458%
  • Status unknown915%
  • Ongoing814%
  • Met its primary endpoint47%
  • Stopped: other or unclear35%
  • Stopped: sponsor or business decision12%

FDA Orphan Designations

Approved first, then open designations, newest first
DateDrugSponsorStatus
Oct 8, 2004LuverisLuveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for…EMD Serono, Inc.Approved

Medicines Authorised in the EU

Newest first
Dec 12, 2016RekovelleFollitropin deltaFerring Pharmaceuticals A/SEMA ↗
Mar 26, 2014BemfolaFollitropin alfa · biosimilarGedeon Richter Plc.EMA ↗
Sep 27, 2013OvaleapFollitropin alfa · biosimilarTheramex Ireland LimitedEMA ↗
Feb 2, 2001OvitrelleChoriogonadotropin alfaMerck Europe B.V.EMA ↗
May 2, 1996PuregonFollitropin betaOrganon N.V.EMA ↗
Oct 20, 1995GONAL-fFollitropin alfaMerck Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.